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Clinical management needs in
teaching hospitalqDear Editor,
The prevalence of hyperglycemia among hospitalized patients is
32%–38% [1]. Observational studies have demonstrated an increase
in complications, hospital stay, and use of resources, despite 30% of
these subjects not having a diagnosis of diabetes mellitus (DM)
[1,2,4]. It is known that insulin plays an important role in the pre-
vention of complications associated with hyperglycemia, and could
be helpful in hospitalized patients with hyperglycemia [3]. Gener-
ally the identiﬁcation of hyperglycemia and treatment strategies
used in the management of hospital hyperglycemia continue to
be deﬁcient because of many barriers [1,4]. Clinical inertia, poor hy-
perglycemia treatment hierarchy, its association with more “atten-
tion demanding” pathologies (miocardic infarctions, among others)
and lack of established algorithms in most hospitals are some ex-
amples of those barriers [4].
The main aim of this study is to present the prevalence of hospi-
tal hyperglycemia in patients on admission as well as the differ-
ences in the treatment, other prognostic variables that affect
hospital stay and mortality and the frequency of DM diagnosis.
We carried out an observational, retrospective study following
the STROBE recommendations. We investigated a convenience
sample in the University Hospital in Monterrey, NL Mexico from
December 2010 to February 2011. Medical records of 269 patients
admitted to different departments of the hospital, were reviewed.
Patients of both sexes were selected consecutively, regardless of
their age. Patients with incomplete records and those admitted to
the Intensive Care Unit were excluded; following the consensus
panel ACE/ADA for glucose target in Non- ICU patients setting [5].
Out of 269 patients that met inclusion criteria, 31 were excluded
because they had no glucose determinations at admission. All
others were analyzed.
Demographic variables, family history of DM and the presence of
cardiovascular risk factors (DM, antihypertensive andhypolipidemic
therapy, smoking, and cardiovascular disease (CVD) and chronic kid-
ney disease (CKD)), in the medical records were collected.
Patients with hyperglycemia were deﬁned as an admission or
in-hospital fasting blood glucose level of 140 mg/dl (7.8 mmol/l)
or greater [5]. Patients with hyperglycemia were subdivided into
known diabetes and new onset hyperglycemia. We identiﬁed the
proportion of patients with an HbA1c determination duringq This is an open access article under the CC BY-NC-ND license (http://
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Open access under CC BY-NC-ND licehospitalization and the type/scheme of treatment (oral, insulin
(infusion, basal/bolus or sliding scale) or combined). In addition,
we recorded the frequency that hyperglycemia was recorded on
the subject’s problem list.
Statistical analysis of the data was performed with SPSS version
19. Continuous variables were expressed with measures of central
tendency and dispersion; in comparisons, Student’s t test and
ANOVA were used. Qualitative variables were expressed in propor-
tions and with the X2 test. A P < 0.05 was considered signiﬁcant.
A total of 269 medical records were reviewed. The demographic
variables and cardiovascular risk factors can be seen in Table 1, both
for overall population and for each glycemic group. The prevalence
of cardiovascular risk factors is more pronounced in the hyperglyce-
mic group, evendoublingor tripling in some factors. Also, themortal-
ity in the hyperglycemic group triples that of normoglycemic group
(5% vs. 15%, P ¼ 0.012). Among the hyperglycemic group, diabetic
and non-diabetic patients show signiﬁcant differences (Table 2).
As it can be expected, a family history of diabetes is twice more com-
mon in the diabetic group. Also, cardiac risk factors such as antihyper-
tensive therapy and hypolipemic agents are more common. It is also
important to note that diabetic, hyperglycemic patients are given
more attention than their not diabetic counterparts, as shown by a
higher prevalence of treatment, follow up and HbA1c on admission.
Finally, mortality in the diabetic group doubles the non diabetic,
although this was found as not statistically signiﬁcant.
The prevalence of hyperglycemia on admission was 35%, similar
to literature [1,15]; however, in contrast, our proportion of de novo
hyperglycemia was almost 50%. In patient hyperglycemia has been
associated with a major risk factor for in hospital mortality, there-
fore we emphasize the need for universal screening of these pa-
tients [3,6,7].
Despite the high prevalence of inpatient hyperglycemia in our
hospitalized population, its management is often considered second-
ary, especially if a history of DM does not exist. This is reﬂected in
problem list of most patients, as 50% did not include hyperglycemia
as amedical problem. If a previous history is suspected, the diagnosis
should be conﬁrmedwith a determination of HBA1c or OGTT [5,8]. In
our results, HbA1c determinations were performed in a small per-
centage of patients with hyperglycemia without DM (12%). Another
major ﬁnding of our study is that, although 85% of diabetic, hypergly-
cemic patients were treated, only a third of those with novo hyper-
glycemia received treatment. Inadequate control of hyperglycemia
has been associated with increased morbidity and mortality [3,6,7].
Established protocols to control inpatient hyperglycemia should be
implemented to reduce these risks [5,7]. We found that most hyper-
glycemic patients received insulin as suggested by most published
guidelines [14]. However, recent studies have shown that the use
of other medications, like DPP-4 inhibitors, could provide the same
amount of efﬁcacy, with less hypoglycemic risks [13].
Finally, our study found inadequate control and follow-up of
hyperglycemia in non-diabetic patients. This is reﬂected as 90% ofnse.
Table 1
Demographic characteristics. Classiﬁcation according to glucose levels on admission.
Variables Overall population
n ¼ 269 (%)
Hypoglycemia
n ¼ 11 (%)
Normal
n ¼ 164 (%)
Hyperglycemia
n ¼ 94 (%)
P value
Gender (W/M) 131 (49)/138 (51) 8 (73)/3 (27) 87 (53)/77 (47) 43 (46)/51 (54) NS
Age 37  21 years 35  17 39  21 52  20 <0.001
Family history of DM 97 (36) 2 (18) 58 (35) 46 (49) 0.034
Smoking 56 (21) 38 (23) 21 (22) NS
Antihypertensive therapy 40 (15) 3 (27) 25 (15) 32 (34) 0.01
Diabetes mellitus 43 (16) 4 (36) 15 (9) 52 (55) <0.001
Hypolipidemic agents 5 (2) 5 (3) 6 (6) NS
CVD 16 (6) 2 (18) 10 (6) 15 (16) 0.026
CKD 1 (9) 10 (6) 17 (18) 0.010
Mortality 1 (9) 8 (5) 15 (16) 0.012
Days of hospital stay 3  2 6  5 6  7 NS
Department
Internal medicine 23 (50) 23 (50)
General surgery 1 (6) 12 (75) 3 (19)
Traumatology 5 (50) 5 (50)
Plastic surgery 6 (60) 4 (40)
Gynecology/Obstetrics 6 (15) 31 (78) 3 (8)
Shock/trauma/observational care unit 4 (3) 79 (59) 51 (38)
Pediatrics 8 (62) 5 (38)
Data presented as means and standard deviation.
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diabetic did.
This bears remarkable importance as it has been reported that
60% of patients admitted to the hospital with hyperglycemia
develop DM within a year after their admission [1].
Our study has limitations, as this is a retrospective study, only
patients with glucose levels on admission were analyzed and we
did not have a follow up of the same population. Another limitation
was that this was a convenience sample being cared by a heterog-
enous group of healthcare providers not a speciﬁc care team.
Also, there was a lack of determination of HbA1c, which is neces-
sary to make a differential diagnosis between stress hyperglycemia
and preexisting DM.
Our study suggests that community hospitals such as ours need
to adopt standardized treatment protocols for inpatientTable 2
The clinical, demographic characteristics and treatment of patients with hyperglyce-
mia according to previous history of DM.
Hyperglycemia
with DM
n ¼ 52 (%)
Hyperglycemia
without DM
n ¼ 42 (%)
P value
Gender (W/M) 27 (52)/25 (48) 16 (38)/26 (62) NS
Age (years) 59  16 44  22 <0.001
Family history of DM 32 (62) 14 (33) 0.006
Smoking 8 (15) 13 (31) NS
Antihypertensive therapy 26 (50) 6 (14) <0.001
Evolution of DM (years) 16  12
Hypolipidemic agents 5 (10) 1 (2) NS
HbA1c request 10 (19) 5 (12) NS
HBA1c (%) 10  2 9  2 NS
Treatment 44 (85) 13 (31) <0.001
Oral treatment 3 (6) NS
Metformin 2 (4) NS
Metformin/Glibenclamide 1 (2) NS
Treatment with insulin 41 (79) 12 (29) <0.001
Infusion pump 13 (25) 4 (10) NS
Sliding scale insulin 13 (25) 6 (14) NS
Basal/bolus insulin 13 (25) 1 (2) NS
Combined therapy 2 (4) 2 (5) NS
Days of hospital stay 6  8 7  6 NS
Mortality 10 (19) 5 (12) NS
Hyperglycemia in PL 14 (27) 2 (5) <0.01
Treatment for DM on discharge 23 (51) 2 (5) <0.001
Appointment at OC for follow-up 18 (35) 2 (5) <0.001
DM: Diabetes mellitus; PL: problem list; OC: outpatient clinic.
Data are presented as means and standard deviation.hyperglycemia. These programs should establish goals for glycemic
control, incorporate algorithms for themanagement of hyper/hypo-
glycemia, promote the use of basal/bolus insulin, adequately docu-
ment the diagnosis, and treat it after hospital discharge [8,9,10,11].
For this reason, in 2009, created a inpatient protocol for hypergly-
cemia entitled called Normoglycemia in the Hospitalized Patient
(NOPHAL), which includes training work to implement an educa-
tional program that includes operational protocols with therapeutic
schemes for hyperglycemia and hypoglycemia, monitoring hospi-
talized patients and quality indicators such as days of hospital
stay and morbidity/mortality [4]. Other resources are available for
treatment of inpatient hyperglycemia, like the AACE Diabetes
Resource Center and others [11,12].
In conclusion, despite the high prevalence of inpatient hypergly-
cemia, there is an obvious lack of screening, ranking, treatment, and
long-term follow-up of in-hospital hyperglycemia.H.E. Tamez-Pérez*
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